1.Research progress on the treatment of in-stent restenosis in coronary drug-eluting stents
Chengwei HU ; Haiyan ZHANG ; Mingzhi LONG
Chinese Journal of Arteriosclerosis 2025;33(8):729-736
With the widespread application of drug-eluting stent(DES)technology and rapid advancement in stent bioengineering,the efficacy and safety of percutaneous coronary intervention(PCI)have significantly improved.Howev-er,the incidence of in-stent restenosis(ISR)remains a critical issue,with approximately 1%to 2%of patients requiring repeat revascularization annually.Given the global implantation of millions of DES each year,ISR has emerged as a major clinical challenge demanding urgent resolution.The pathological mechanisms underlying DES-ISR are complex and heter-ogeneous,and with continuous progress in intracoronary imaging techniques,these mechanisms and classifications have been further elucidated.Concurrently,therapeutic tools and strategies for ISR are undergoing ongoing development and optimization.This review summarizes recent research progress and achievements in the definition,classification,patho-logical mechanisms,imaging characteristics,and treatment approaches related to DES-ISR.
2.A Case of Hepatic Angiosarcoma
Linhao ZHANG ; Chengwei TANG ; Zhiyin HUANG
JOURNAL OF RARE DISEASES 2025;4(2):263-268
Hepatic angiosarcoma is a rare,highly malignant tumor originating from liver blood vessels or lymphatic vessels.Its clinical manifestations and imaging examinations are not specific,and pathological biopsy is needed to confirm the diagnosis.This article reports a 47-year-old male patient with hepatic angiosarcoma,who has clinical manifestations of abdominal pain,jaundice,and disseminated intravascular coagulation.The CT and MRI findings of this patient are similar to hepatic sinusoidal obstruction syndrome.Relevant literature on hepatic angiosarcoma in recent years was reviewed.The manifestations,diagnosis and treatment of hepatic angiosarcoma were summarized to improve clinicians'understanding of the disease.
3.Prediction of Expression of Ki-67 Status in Breast Cancer via Deep Learning-Based Radiomics Model
Hanmin XIE ; Jialing CHENG ; Yuelong LI ; Chengwei LI ; Chaoxiang YANG ; Ruoxian ZHANG
Chinese Journal of Medical Imaging 2025;33(10):1049-1055
Purpose To analyze the value of a deep learning(DL)radiomics model based on dynamic contrast-enhanced MRI images in predicting the expression of Ki-67 status in breast cancer.Materials and Methods A retrospective analysis of 152 breast cancer patients confirmed by pathological results at Guangdong Women and Children Hospital,MRI images and clinical pathological data were reviewed,and based on postoperative immunohistochemistry results,the images of the high and low expression groups of Ki-67 were randomly sampled in a ratio of 8∶2 to form a training set of 122 cases and a validation set of 30 cases.Single-factor and multi-factor Logistic regression analyses of clinical data were performed to select independent predictors of breast cancer expressing Ki-67 status.The ResNet-18 model was used as the basic model for DL feature extraction.Hand-crafted radiomic features and DL features were extracted.Eight machine learning models were constructed based on clinical features,hand-crafted radiomic features,DL features,and their combinations.The area under the receiver operating characteristic curve was used to evaluate the predictive performance of the models,and the best model was determined as the output model.Results The progesterone receptor status(OR=0.764,P=0.040)and human epidermal growth factor receptor-2 status(OR=1.187,P=0.046)were independent clinical predictors of breast cancer expressing Ki-67 status.The combined feature models demonstrated superior performance over the individual feature models,and the support vector machine algorithm had the highest prediction performance in the validation set,with an area under the curve of 0.847.Conclusion The DL radiomics model based on dynamic contrast-enhanced MRI images can effectively predict the expression of Ki-67 status in breast cancer.The support vector machine algorithm combined with feature model is the best,which can help the clinical diagnosis and treatment of breast cancer and prognosis evaluation.
4.The influence of two-way referral model on treatment and prognosis of patients with chronic heart failure
Yijun SUN ; Xinyu ZHANG ; Yue HU ; Zongwei LIN ; Jie XIAO ; Peng LI ; Xin ZHAO ; Huafang ZHANG ; Bo QIN ; Dequan JIA ; Tao ZHANG ; Jian MA ; Hongping CHEN ; Chunju ZHANG ; Xinwei GENG ; Kaiyan ZHANG ; Man ZHENG ; Fenglei ZHANG ; Yan LANG ; Hegong HOU ; Peng LIU ; Haifeng JIA ; Jianjun LU ; Kai ZHAO ; Hui ZHAO ; Jiechang XU ; Mi ZHANG ; Xiuxin LI ; Dongxia ZHANG ; Lin ZHONG ; Hui ZHAO ; Fangfang LIU ; Yan LIU ; Dongxia MIAO ; Chengwei WANG ; Hui ZHANG ; Chen WANG ; Fen WANG ; Xuejuan ZHANG ; Huixia LYU ; Xiaoping JI
Chinese Journal of Cardiology 2025;53(11):1244-1253
Objective:To explore the impact of the two-way referral model on compliance and prognosis in patients with heart failure.Methods:This bidirectional cohort study enrolled chronic heart failure (CHF) patients treated at Qilu Hospital of Shandong University or designated primary hospitals between March 2018 and March 2022. Patients were categorized into two groups based on referral status: two-way referral group (participating in the referral model with≥1 follow-up visit at primary hospitals) and the core hospital group (receiving treatment and follow-up exclusively at Qilu Hospital). Baseline clinical characteristics were collected and compared between groups. Patients underwent followed-up, with primary endpoints including follow-up rate, drug (β-blockers, angiotension converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists) utilization rate and target dose achievement rate. Secondary endpoints encompassed changes from baseline in left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDd), and N-terminal pro-brain natriuretic peptide (NT-proBNP), plus cardiovascular mortality and heart failure rehospitalization. Generalized linear mixed models analyzed longitudinal trends in LVEF, LVEDd, and NT-proBNP levels. Kaplan-Meier curves and Cox regression evaluated LVEF recovery rates, supplemented by subgroup analyses. Multivariate logistic regression was used to identify factors influencing target dose achievement rate for β-blockers and ACEI/ARB/ARNI therapies in CHF patients.Results:A total of 357 patients were enrolled, aged 53 (41, 63) years, including 256 males (71.7%). 157 patients were in the two-way referral group and 200 patients in the core hospital-treated group. Compared with the core hospital-treated group, the two-way referral group had lower baseline LVEF (28 (22, 34)% vs. 31 (23, 36)%, P=0.021) and systolic blood pressure (116 (104, 125) mmHg vs. 121 (109, 134) mmHg (1 mmHg=0.133 kPa), P=0.010). The 12-month follow-up rate of the two-way referral group was higher than the core hospital-treated group (73.8% vs. 56.0%, P=0.004). No significant between-group differences were observed in drug utilization rate of β-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all P>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups. Although the core hospital-treated group had higher target dose achievement rates for β-blockers (65.4% vs. 49.3%, P=0.042) and ACEI/ARB/ARNI (79.8% vs. 65.8%, P=0.046) than the two-way referral group, multivariate logistic regression indicated that the two-way referral model was not a negative predictor for these outcomes (all P>0.05). Both groups showed improved NT-proBNP, LVEDd, and LVEF from baseline (all P<0.001) with no significant difference in trends between groups (all P>0.05). There was no significant difference in the composite incidence (7.6% vs. 6.5%, P=0.674) and cumulative incidence (log-rank P=0.684) of cardiovascular death and heart failure rehospitalization at 12 months between two groups. Conclusion:The two-way referral model demonstrates advantages in improving medication adherence, drug utilization rates, and targetdoseachievement rates among CHF patients. This model not only promotes cardiac functional recovery but also reduces risks of cardiovascular mortality and heart failure rehospitalization, achieving comparable therapeutic and management outcomes to those observed in core hospital-treated patients.
5.Research Progress of Clinical Quality Control Phantoms for MRI Equipment
Chengwei LI ; Jiao LI ; Hui XU ; Tianrui ZHAO ; Pu ZHANG ; Peng ZHANG ; Zhengshan HUANG ; Jie SUN
Chinese Journal of Medical Imaging 2025;33(6):607-610,617
With the rapid increase of MRI systems in hospitals in China,national multi-sectoral strategies have been put forward to clarify requirements for improving image quality of MRI systems and preventing application risks in clinic.Quality control of MRI systems becomes an important task for regulators as well as hospital radiology departments.The tools used for quality control include imaging performance phantom and specialized function phantom,which can realize detection or calibration for parameters such as high contrast resolution,image uniformity and relaxation time.This article mainly reviews the research progress of the operation principles,common types and clinical applications for these two types of phantoms mentioned above.
6.Analysis of the efficacy of lamb′s tripe extract and vitamin B 12 capsule on chronic atrophic gastritis at different sites
Dongdong XIA ; Huahong XIE ; Bo JIANG ; Hong XU ; Zhanguo NIE ; Chengwei TANG ; Qiang GUO ; Xiaoping ZOU ; Shuisheng SHI ; Tao SUN ; Shourong SHEN ; Guoqing LI ; Xiaozhong GUO ; Xiaoyan ZHAO ; Jiaming QIAN ; Weixing CHEN ; Guiying ZHANG ; Aijun LIAO ; Jingyuan FANG ; Daiming FAN ; Kaichun WU
Chinese Journal of Digestion 2025;45(3):162-168
Objective:To evaluate the efficacy of lamb′s tripe extract and vitamin B 12 capsule (LTEVB 12C) on chronic atrophic gastritis (CAG) at different locations (antrum lesser curvature, antrum greater curvature, gastric angle, corpus lesser curvature, and corpus greater curvature). Methods:From August 2011 to January 2013, 715 patients with CAG in a multicenter, randomized, double-blind, placebo-controlled trial were enrolled from 16 tertiary first-class hospitals across the country, including the First Affiliated Hospital of Air Force Medical University, Nanfang Hospital of Southern Medical University, the First Hospital of Jilin University, West China Hospital of Sichuan University, etc., there were 476 cases in the LTEVB 12C group and 239 cases in the placebo group. The patients of the LTEVB 12C group received LTEVB 12C, and the patients of placebo group received LTEVB 12C mimetic, all the medications were taken 3 capsules each time and 3 times a day after meals, and the treatment course of 2 groups were both 6 months. The efficacy evaluation criteria included the effective rate (a decrease of ≥1 in histopathological score compared with baseline after 6 months of treatment) and the reversal rate (a decrease of ≥ 2 in histopathological score compared with baseline after 6 months of treatment in the patients with moderate to severe CAG). The impact of lesion sites on the therapeutic effects of LTEVB 12C was analyzed by logistic regression analysis. The two-way unordered Cochran-Mantel-Haenszel chi-square test considering the center effect and Pearson chi-square test were used for statistical analysis. Results:The effective rates of chronic inflammation at the antrum greater curvature and corpus greater curvature (23.3%, 110/473 vs. 13.0%, 31/239; 20.3%, 96/472 vs. 12.6%, 30/239), the effective rates of atrophy at the antrum lesser curvature, antrum greater curvature, gastric angle, corpus lesser curvature, and the corpus greater curvature (27.0%, 118/437 vs. 15.7%, 34/216; 29.2%, 126/432 vs. 18.5%, 38/205; 27.8%, 121/435 vs. 16.7%, 36/216; 32.5%, 127/391 vs. 19.8%, 37/187; 33.0%, 119/361 vs. 21.8%, 39/179), and the effective rates of intestinal metaplasia at the antrum lesser curvature, antrum greater curvature, gastric angle, and the corpus lesser curvature (45.0%, 112/249 vs. 29.8%, 31/104; 53.8%, 86/160 vs. 33.9%, 21/62; 45.8%, 103/225 vs. 24.0%, 25/104; 51.9%, 83/160 vs. 28.3%, 17/60) of the LTEVB 12C group were all higher than those of the placebo group, and the differences were statistically significant ( χ2=10.76, 6.39, 9.69, 7.91, 11.05, 9.62, 8.57, 5.20, 7.11, 12.45, and 6.73; all P<0.05). The reversal rates of chronic inflammation at the corpus lesser curvature and corpus greater curvature (5.2%, 12/231 vs. 0, 0/123; 4.7%, 8/170 vs. 0, 0/88), the reversal rates of atrophy at the antrum lesser curvature, antrum greater curvature, corpus lesser curvature, and the corpus greater curvature (6.8%, 22/323 vs. 1.3%, 2/151; 9.2%, 29/315 vs. 1.4%, 2/144; 14.2%, 38/267 vs. 2.5%, 3/121; 20.8%, 35/168 vs. 5.8%, 4/69), and the reversal rates of intestinal metaplasia at the antrum lesser curvature, antrum greater curvature, gastric angle, and the corpus lesser curvature (29.8%, 39/131 vs. 9.1%, 4/44; 41.0%, 32/78 vs. 12.5%, 3/24; 33.3%, 44/132 vs. 4.8%, 3/63; 50.0%, 37/74 vs. 8.7%, 2/23) of the LTEVB 12C group were all higher than those of the placebo group, and the differences were statistically significant ( χ2=6.58, 5.12, 5.60, 8.61, 11.43, 6.59, 7.30, 4.95, 15.92, 7.62; all P<0.05). There were no statistically significant differences in the effective rates and reversal rates of active inflammation at different locations between the LTEVB 12C group and the placebo group (all P>0.05). The results of logistic regression analysis (taking the antrum lesser curvature as the reference) further confirmed that the reversal rates of chronic inflammation ( OR=0.22, 95% confidence interval (95% CI): 0.07 to 0.67; OR=0.24, 95% CI: 0.07 to 0.80), atrophy ( OR=0.28, 95% CI: 0.16 to 0.49; OR=0.28, 95% CI: 0.16 to 0.49), and intestinal metaplasia ( OR=0.42, 95% CI: 0.24 to 0.77; OR=0.20, 95% CI: 0.08 to 0.52) at the corpus lesser curvature and corpus greater curvature were all higher than those at the antrum lesser curvature, and the differences were statistically significant (all P<0.05). There were no statistically siginificant differences in the reversal rates of the aforementioned pathological features between the antrum greater curvature, gastric angle, and the antrum lesser curvature (all P>0.05). Conclusion:LTEVB 12C can achieve good efficacy in the treatment of CAG, and the chronic inflammation, atrophy, and intestinal metaplasia at multiple locations are improved, especially at the corpus lesser curvature and the corpus greater curvature.
7.Strengthening the Construction of Clinical Quality Control System for MRI Equipment to Ensure Their Efficacy in Clinical Application
Hongxia YIN ; Chengwei LI ; Yawen LIU ; Hui XU ; Yu ZHANG ; Zhenchang WANG
Chinese Journal of Medical Imaging 2025;33(6):583-586
With the rapid increase in the ownership of MRI equipment in China,quality control,particularly in clinical usage aspects,has become critically important.For clinical quality control of MRI systems,it is essential to establish comprehensive workflow principles encompassing multiple elements such as personnel,equipment,standards,tools and methodologies.To advance the standardization and widespread adoption of clinical quality control for MRI equipment,efforts must focus on strengthening regulatory frameworks,advancing phantom research,development and enhancing professional expertise.Concurrently,continuous improvements in training programs and supervision mechanisms are necessary to ensure the effective implementation of MRI clinical quality control practices.Furthermore,in the era of digital healthcare,clinical quality assurance for MRI equipment is evolving toward automation and intelligent solutions,providing higher-quality and more efficient assurance for clinical applications.
8.Whole-Body Specific Absorption Rate Measurement Method Based on NIM Calorimetry
Zhengshan HUANG ; Pu ZHANG ; Peng ZHANG ; Chengwei LI ; Jie SUN
Chinese Journal of Medical Imaging 2025;33(6):589-594
Purpose To explore the feasibility and practical value of using National Institute of Metrology(NIM)calorimetry method to measure whole-body specific absorption rate(SAR)values of in-service MRI equipment.Materials and Methods A NIM calorimetry device for measuring whole-body SAR values was developed,SAR values of different MRI devices were measured by NIM calorimetry,and compared with National Electrical Manufacturers Association(NEMA)calorimetry and pulse-energy method to verify the measurement accuracy and applicability of the NIM calorimetry method.Results The NIM calorimetry device developed in this study had reliable performance,and the experimental results indicated the difference in measurement results between NIM calorimetry(1.63 W/kg)and NEMA calorimetry(1.80 W/kg)was within 10%.The difference between the SAR measurement results of multiple MRI devices based on NIM calorimetry(0.46,0.93,0.61 W/kg)and the pulse energy method(0.42,0.89,0.56 W/kg)was within 10%.Conclusion The NIM calorimetry method in this study can accurately measure whole-body SAR values and has applicability.
9.Research progress on the treatment of in-stent restenosis in coronary drug-eluting stents
Chengwei HU ; Haiyan ZHANG ; Mingzhi LONG
Chinese Journal of Arteriosclerosis 2025;33(8):729-736
With the widespread application of drug-eluting stent(DES)technology and rapid advancement in stent bioengineering,the efficacy and safety of percutaneous coronary intervention(PCI)have significantly improved.Howev-er,the incidence of in-stent restenosis(ISR)remains a critical issue,with approximately 1%to 2%of patients requiring repeat revascularization annually.Given the global implantation of millions of DES each year,ISR has emerged as a major clinical challenge demanding urgent resolution.The pathological mechanisms underlying DES-ISR are complex and heter-ogeneous,and with continuous progress in intracoronary imaging techniques,these mechanisms and classifications have been further elucidated.Concurrently,therapeutic tools and strategies for ISR are undergoing ongoing development and optimization.This review summarizes recent research progress and achievements in the definition,classification,patho-logical mechanisms,imaging characteristics,and treatment approaches related to DES-ISR.
10.A Case of Hepatic Angiosarcoma
Linhao ZHANG ; Chengwei TANG ; Zhiyin HUANG
JOURNAL OF RARE DISEASES 2025;4(2):263-268
Hepatic angiosarcoma is a rare,highly malignant tumor originating from liver blood vessels or lymphatic vessels.Its clinical manifestations and imaging examinations are not specific,and pathological biopsy is needed to confirm the diagnosis.This article reports a 47-year-old male patient with hepatic angiosarcoma,who has clinical manifestations of abdominal pain,jaundice,and disseminated intravascular coagulation.The CT and MRI findings of this patient are similar to hepatic sinusoidal obstruction syndrome.Relevant literature on hepatic angiosarcoma in recent years was reviewed.The manifestations,diagnosis and treatment of hepatic angiosarcoma were summarized to improve clinicians'understanding of the disease.

Result Analysis
Print
Save
E-mail